美股异动 | 睡眠呼吸暂停药物研发商Apnimed(APMD.US)登陆美股市场 开盘股价涨超11%

智通财经
Aug 01
【美股异动 | 睡眠呼吸暂停药物研发商Apnimed(APMD.US)登陆美股市场 开盘股价涨超11%】智通财经APP获悉,周五,专注于阻塞性睡眠呼吸暂停治疗的美国生物科技公司Apnimed(APMD.US)登陆美股市场,开盘股价涨超11%,报17.79美元。IPO价格为16美元。Apnimed目前正开发治疗阻塞性睡眠呼吸暂停的口服药物Oxnimbi。公司已于今年4月向美国食品药品监督管理局(FDA)提交上市申请,预计监管审批周期约为10个月。若获批上市,Oxnimbi将成为继礼来(LLY.US)减重药Zepbound之后,市场上少数获批用于治疗睡眠呼吸暂停的药物之一,并将与其展开竞争。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10